Dr Kay Roy graduated in medicine in 2000 from the University of Manchester. She was subsequently awarded a PhD in 2008 for research on characterisation of patients with chronic obstructive pulmonary disease (COPD). Her specialist respiratory training was undertaken in the Cambridge deanery.
She was appointed as a consultant in West Hertfordshire before moving in 2020 to lead the asthma service at UCLH. She is also Lead for UCLH's smoking cessation service. Dr Roy supports the complex infection service led by Professor Jeremy Brown and the interstitial lung Disease service led by Professor Jo Porter.
In her current role as an integrated respiratory physician, Dr Roy works closely with the community services involved in COPD care. She is also a member of the respiratory focus group at North Central London CCG and helps to run the specialist lung volume reduction MDT for emphysema.
Dr Roy has been the principal investigator on a number of multicentre clinical trials in COPD and asthma. Her current external duties include roles within the British Thoracic Society, in which she is a member of the quality improvement committee and the pulmonary infection specialist advisory group.
In 2019-2020 she has been a finalist for awards from The British Thoracic Society, The Health Service Journal and The British Medical Journal, for work on community-based projects around COPD exacerbations and point of care testing for infection.
Chronic obstructive pulmonary disease, asthma and pulmonary infections
Selected original manuscripts in peer reviewed journals
1. Michael G. Crooks, Jack Elkes, William Storrar, Kay Roy, Mal North, Alison Blythin, Alastair Watson, Victoria Cornelius, Tom M.A. Wilkinson. Evidence generation for the clinical impact of myCOPD in patients with mild, moderate and newly diagnosed COPD: a randomised controlled trial. ERJ Open Research 2020 6: 00460-2020; DOI: 10.1183/23120541.00460-2020
2. Roy K., Borrill Z., Starkey C., Hazel A.L., Morris J., Vestbo J., Singh D. Use of different exhaled nitric oxide multiple flow rate models in COPD. Eur Respir J 2007 Apr; 29(4): 651-9.
3. Roy K, Smith J, Kolsum U, Borrill Z, Vestbo J, Singh D. COPD phenotype description using principal components analysis. Respir Res. 2009 May 29; 10:41.
4. Borrill Z, Roy K, Kolsum U, Southworth T, Vestbo J, Singh D. Seretide withdrawal increases airway inflammation in moderate COPD patients. Eur J Clin Pharmacol. 2009 Jul 15.
5. Kolsum U., Roy K, Starkey C, Borrill ZL, Truman N, Vestbo J, Singh D. The repeatability of interleukin-6, tumour necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Into J Chron Obstruct Pulmon Dis. 2009;4(1):149-56.
6. Kolsum U., Borrill ZL, Roy K, Starkey C, Vestbo J, Houghton C., Singh D. Impulse oscillometry in COPD: Identification of measurements related to airway obstruction, airway conductance and lung volumes. Respir Med 2009 Jan;103(1):136-43.
7. Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008 Aug; 32(2): 472-86.
8. Singh D., Fairwood J., Murdoch R., Weeks A., Russell P., Roy K., Langley S., Woodcock A. The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naïve asthmatics. Br J Clin Pharmacol 2008 Aug; 66(2): 261-5
9. Borrill ZL, Roy K, Vessey RS, Woodcock AA, Singh D. Non invasive biomarkers and pulmonary function in smokers. Into J Chron Obstruct Pulmon Dis. 2008; 3(1): 171-83.
10. Chew JRY, Roy K, Babar J, Mahadeva R. An unusual case of rapid radiological progression of bullous emphysema secondary to severe ?1-antitrypsin deficiency. BMJ Case Rep 2015. doi:10.1136/bcr-2015-209346